VTR Stock Recent News
VTR LATEST HEADLINES
REITs finished the first quarter of 2025 in the red (-3.36%) with a brutal -4.92% average total return in March. Large cap (-2.04%) and mid cap REITs (-2.63%) saw modest losses, but small caps (-4.16%) and micro caps (-16.19%) had a particularly bad month. Only 29.49% of REIT securities had a positive total return in March.
First-quarter earnings season is in full swing. But investors playing the long game want to know which S&P 500 companies will profit most.
Aging population, rising healthcare expenses, favorable outpatient visit trends and accretive investments in its research portfolio are likely to support VTR.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Ventas is a well-run REIT that's experiencing high growth, particularly in its SHOP portfolio. It carries a strong balance sheet and management has resumed meaningful dividend growth. The recent dip in price has brought the yield to 3%. Combined with high single digit FFO/share growth, VTR could deliver potential market-beating total returns.
CHICAGO--(BUSINESS WIRE)--Ventas, Inc. (NYSE: VTR) will issue its first quarter 2025 earnings release after the close of trading on the New York Stock Exchange on Wednesday, April 30, 2025. A conference call to discuss those earnings will be held on Thursday, May 1, 2025 at 10:00 a.m. Eastern Time (9:00 a.m. Central Time). The dial-in number for the conference call is (888) 330-3576 (or +1 (646) 960-0672 for international callers), and the participant passcode is 7655497. A live webcast can be.
Rising healthcare expenditures and an aging population support VTR's senior housing operating portfolio despite competition and tenant concentration risks.
Jim Cramer breaks down why he's keeping an eye on shares of Ventas.
Ventas (VTR) reported earnings 30 days ago. What's next for the stock?
VTR is set to gain from rising healthcare spending amid an aging population. Accretive investments in the research portfolio and solid balance sheet bode well.